Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination

Rhea-AI Summary

Evaxion Biotech (NASDAQ: EVAX) has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement, avoiding delisting. The company has strengthened its financial position through several capital market activities:

- Completed a $10.8 million public offering on January 31, 2025 - Raised approximately $7.6 million through prefunded warrants and ATM facility sales - Total net proceeds of $17 million, extending cash runway to mid-2026

Additionally, Evaxion is in discussions with the European Investment Bank (EIB) regarding the conversion of €3.5 million of its €7 million loan, expected to increase equity by $3.7 million upon completion in Q1 2025. Nasdaq has implemented a one-year Mandatory Panel Monitor to ensure continued compliance.

Positive

• Successfully avoided Nasdaq delisting by meeting minimum equity requirements
• Raised $17 million through public offering and warrant exercises
• Extended cash runway to mid-2026
• Potential $3.7 million equity increase from EIB loan conversion in Q1 2025

Negative

• Subject to one-year Mandatory Panel Monitor by Nasdaq
• Immediate delisting risk if equity falls below requirements during monitoring period

Insights

Financial Analyst

The successful resolution of Evaxion's Nasdaq compliance challenge represents a important turning point for the clinical-stage biotech company. Through a well-executed series of capital raising initiatives, including a $10.8 million public offering and $7.6 million from warrant exercises and ATM sales, the company has not only met but exceeded Nasdaq's minimum equity requirements.

The extension of the cash runway to mid-2026 is particularly significant in the current biotech funding environment, where capital access remains challenging. This runway provides Evaxion with approximately 16 months of operational flexibility, a substantial buffer for advancing their AI-powered vaccine development programs without immediate funding pressure.

The pending EIB loan conversion of €3.5 million to equity would further strengthen the balance sheet while reducing debt obligations. However, investors should note the one-year mandatory panel monitor period, which introduces a strict compliance framework with immediate delisting risks if equity falls below requirements.

The successful compliance restoration, combined with the improved cash position, positions Evaxion more favorably for potential strategic partnerships or additional capital raises, should they be needed. This financial restructuring demonstrates management's ability to execute under pressure and maintain access to public markets, which is important for a clinical-stage biotech company's long-term development plans.

• Evaxion will remain listed on Nasdaq after successfully evidencing compliance with the Nasdaq minimum stockholders’ equity requirement 
• Evaxion has restored its equity above the minimum requirement through capital market activities
• Evaxion’s cash runway now extends to mid-2026
• The conversion of Evaxion’s EIB loan to equity is still expected to be completed in Q1 2025, which is anticipated to further boost equity

COPENHAGEN, Denmark, February 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has received confirmation from the Nasdaq Stock Market LLC (“Nasdaq”) that it has re-established compliance with Nasdaq’s minimum stockholders’ equity requirement. Nasdaq has withdrawn its determination to delist Evaxion, and the company will remain listed as fully compliant with Nasdaq’s rules.

“We are very pleased to have received formal confirmation that we are again fully compliant with Nasdaq’s rules and will remain listed as we always planned for. We thank Nasdaq for a constructive dialogue on the matter. Having significantly strengthened our equity and cash position, full focus is now on executing upon our strategy and pursuing our 2025 milestones”, says Christian Kanstrup, CEO of Evaxion.

On January 28, 2025, Evaxion was given until May 12, 2025, to formally evidence compliance with Nasdaq listing rule 5550(b)(1) requiring stockholders’ equity of at least $2.5 million. The company has already successfully executed its plan to restore its equity and has re-established compliance.

In line with the applicable Nasdaq rules in such circumstances, the notice also indicated that Nasdaq had imposed a “Mandatory Panel Monitor,” as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), for a period of one year from the date of the compliance determination, pursuant to which in the event Evaxion fails to timely satisfy the minimum stockholders’ equity requirement during the one-year monitor period, Evaxion will not have the opportunity to provide a compliance plan for Nasdaq Staff’s review; rather, Nasdaq would instead issue a delist determination pursuant to which Evaxion could request a hearing and stay of the delist determination pending another hearing before the Panel.

On January 31, 2025, Evaxion completed a $10.8 million public offering. In the weeks before, exercise of prefunded warrants and sales of American Depositary Shares through Evaxion’s ATM facility had also bolstered the company’s equity by approximately $7.6 million. In total, these capital market activities provided a net total of approximately $17 million in cash and equity, extending Evaxion’s cash runway to mid-2026.

Evaxion remains in discussions with the European Investment Bank (EIB) about the conversion of €3.5 million out of Evaxion’s €7 million loan with EIB, which is expected to increase Evaxion’s equity by $3.7 million (€3.5 million) immediately upon completion. An agreement between Evaxion and EIB would be subject to certain conditions and is still expected to be finalized and implemented in the first quarter of 2025.

Contact information 
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About EVAXION
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

FAQ

How much capital did Evaxion Biotech (EVAX) raise in its recent financing activities?

Evaxion raised approximately $17 million in total, comprising a $10.8 million public offering completed on January 31, 2025, and approximately $7.6 million through prefunded warrants and ATM facility sales.

What is the new cash runway extension for Evaxion (EVAX) following recent fundraising?

Following the recent $17 million capital raise, Evaxion's cash runway has been extended to mid-2026.

How much is the expected equity increase from Evaxion's (EVAX) EIB loan conversion?

The conversion of €3.5 million from the EIB loan is expected to increase Evaxion's equity by $3.7 million upon completion in Q1 2025.

What are the terms of Nasdaq's Mandatory Panel Monitor for Evaxion (EVAX)?

Nasdaq imposed a one-year Mandatory Panel Monitor, during which if Evaxion fails to maintain minimum stockholders' equity requirements, it will face immediate delisting determination without the opportunity to provide a compliance plan.